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Abstract
Introduction
Certain ABO blood types have been linked to cardiovascular disease, infection and cancers.
The effect of recipient ABO blood group on patient and graft survival has not been studied in
ABO-matched kidney transplantation. This study aims to determine the association between
kidney transplant recipient ABO blood groups with patient and graft survival in Australian
and New Zealand.
Methods
All Australian and New Zealand transplant recipients who received ABO-compatible primary
kidney transplants between 1995–2016 were analysed using a de-identified dataset from
the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. Primary anal-
ysis was undertaken of recipient ABO blood group O versus non-O blood groups. The pri-
mary outcome was patient survival post kidney transplantation and the secondary outcome
was death censored graft survival. Recipient age at first transplant, gender, ethnicity, body
mass index, smoking status, vascular disease, presence of diabetes mellitus, chronic lung
disease, primary kidney disease, donor source, donor age and gender, and era of trans-
plants were included in the multivariate model as confounders.
Results and conclusions
On analysis of 15,523 kidney transplant recipients, blood group O was not associated with
patient survival (hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.89–1.04) nor death
censored graft survival (HR 0.97, 95% CI 0.89–1.05) compared to non-blood group O recipi-
ents. Competing risks analyses showed an increased risk of cancer-related mortality in
blood group O recipients on univariate analyses (HR 1.18, 95% CI 1.01–1.37) however, this
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became insignificant on multivariate analyses. On secondary analyses, recipient blood
group AB (4.11% participants) was associated with inferior death censored graft survival
compared to those with blood group O (HR 1.24, 95% CI 1.02–1.50). Although recipient
ABO blood groups were not associated with patient nor graft survival, differences in cause-
specific mortality between individual blood groups cannot be excluded based on current
analyses.
Introduction
The ABO blood group system consists of complex carbohydrate molecules expressed on the
extracellular surface of red blood cell membranes [1]. The primary structure of these antigens
is a glycoprotein or glycolipid backbone called the H structure. The A and B alleles encode for
different glycosyltransferases which attach specific monosaccharides (A = N-acetylgalactosa-
mine, B = D-galactose) to the H structure to form the A and B antigens [2]. The O allele do not
encode a functional enzyme so the O antigen consists of the unaltered H structure. Notably,
ABO antigens are also expressed on epithelium, sensory neurons, platelets and vascular endo-
thelium [3, 4].
It follows that ABO blood group had implications for cardiovascular disease, cancer and
infections [5]. Non-O blood type individuals have increased risks of venous thrombosis,
peripheral vascular disease, coronary heart disease, myocardial infarction and ischaemic stroke
[6, 7]. This has been attributed to increased von Willebrand’s factor half-life associated with A
and B antigens; as well as higher levels of vWF and factor VIII in non-O blood type individuals
[5, 8, 9]. Blood group O was associated with increased prevalence of skin cancers and non-
Hodgkin’s lymphoma [10–12]. Blood group O has been associated with increased risks of
disease progression in patients with bladder cancer [13, 14]. Lastly, blood group O has been
correlated to increased risk of cholera, mumps and tuberculosis; while blood group A are at
increased risk of Pseudomonas aeruginosa infections [15, 16]. This has been attributed to the
role of blood group antigens as receptors and/or coreceptors for pathogens and facilitate intra-
cellular uptake [16].
To date, no study has investigated the relationship between ABO blood group and ABO-
compatible kidney transplant outcomes despite persistent differences in transplantation wait-
time between different ABO blood groups. This study seeks to complete an analysis of kidney
transplants conducted in Australia and New Zealand between 1995–2016 to determine the
effect of ABO blood groups on patient survival and identify other interacting factors may
impact on post-transplant outcomes. Lastly, this study will review patient factors that could
contribute to ABO blood group-related decrements in patient survival.
Materials and methods
Data collection
All Australian and New Zealand transplant recipients who received ABO-compatible primary
kidney transplants (living and deceased) between 1995–2016 were analysed using a de-identi-
fied dataset from the Australia and New Zealand Dialysis and Transplant (ANZDATA) Regis-
try. ABO-compatible kidney transplants included ABO-matched, donor blood group O and
recipient blood group AB transplants (S1 Table). All transplanting units in Australia and
New Zealand contribute to the ANZDATA Registry. Research was approved by ANZDATA
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executive (ID 42058) and Royal Adelaide Hospital Human Research Ethics Committee
(HREC/17/RAH/408 R20170927). Written consent was not obtained as all data received from
ANZDATA was fully anonymized prior to analysis.
Statistical analysis
The main exposure variable was the cohort identified by recipient ABO blood group: blood
group O versus non-blood group O. Secondary analyses compared each ABO blood group to
blood group O. Covariates included: recipient’s age at first transplant, gender, ethnicity, body
mass index (BMI), smoking status, vascular disease, presence of diabetes mellitus, chronic
lung disease, primary kidney disease; donor source, age, ethnicity and gender, and era of trans-
plants (1995–1999, 2000–2004, 2005–2009, 2010–2015). Comorbidities, BMI and smoking sta-
tus were recorded at time of transplant. Vascular disease was categorised by the presence of at
least one of ischemic heart disease, cerebrovascular disease and/or peripheral vascular disease.
Ethnicity and gender were classified by patient’s self-identification on registration forms. Pri-
mary renal disease were as identified by treating clinicians on ANZDATA data entry forms
based on renal biopsy results and/or clinical features.
The primary outcome was patient survival post kidney transplantation and the secondary
outcome was death censored graft survival. Patient survivals were measured from the date of
transplant to the date of death, patients were censored at date of loss to follow-up or 31st of
December 2016. Death censored graft survivals were calculated from the date of transplant to
the date of irreversible graft failure signified by long-term dialysis (or re-transplantation) or
the date of last follow-up during the period when the graft was still functioning. In the event of
death with a functioning graft, the follow-up period is censored at the date of death.
All statistical analyses were performed using Stata statistical software, version 15.1. Patient’s
characteristics at transplant were expressed as median and intra quartile range (IQR) for contin-
uous skewed data and proportions were presented as percentages of the respective denominator.
Cox proportional hazard models were applied to examine the survival outcomes between
groups. Multivariate modelling was then undertaken by adding previously listed covariates.
Transplant waiting times were included as a continuous variable. The estimates were calcu-
lated using the likelihood ratio method and were expressed as hazard ratios (HRs). Propor-
tional hazard assumption was tested by log-log plot of survival and Schoenfeld Residuals.
Survival curves between blood groups were evaluated by standard Kaplan–Meier survival
curves and groups were compared by log-rank test. The departure from linearity for continu-
ous predictors was tested by linear spline for the adaptive model and found an evidence that
the assumption of linearity had been violated (Wald test p-values >0.05). Linear splines with
knots at specified points were applied for non-linear relationships.
Competing risk analysis was performed on causes of survival outcomes between groups. In
the competing risk set up, under each cause for the occurrence of an event of interest, a hazard
function in the presence of confounders is considered. The causes other than the cause of
interest are considered as competing events. Survival times are defined as the time until occur-
rence of one competing event preventing other event to occur. Fine and Gray subdistribution




15,523 patients received primary kidney transplants between 1995 to 2016. Blood group O
comprised of 44.1% of recipients (n = 6,839), blood group A comprised of 39.7% (n = 6,166),
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blood group B comprised of 11.4% (n = 1,769) and blood group AB comprised of 4.1%
(n = 639) (Table 1). Recipients with blood group B and AB were more likely to be Asian than
white compared to blood groups O and A recipients. Median dialysis duration was the shortest
for recipients with blood group A (1.6 years) and longest for blood group O (2.3 years) how-
ever, blood group AB recipients were most likely to receive a graft within 5 years (95.2%).
Median total ischaemia time was greatest for AB group grafts (11.0 hours). Blood group AB
recipients were more likely to receive deceased donor kidneys (74.6%). Recipient age group,
gender, primary renal disease, smoking status, vascular disease, diabetes, respiratory disease
and transplant era were similar between recipient blood groups. Cardiovascular death (29%)
was the most common cause of death in the study period followed by cancer (22%) and infec-
tion (18%).
Recipient blood group O not associated with differences post-transplant
patient survival
Blood group O recipients had similar post-transplant survival compared to non-blood group
O recipients (HR 0.96, 95% CI 0.89–1.04, Fig 1A, S2 Table). Increasing age at transplant, BMI
<18.5, Aboriginal and Torres Strait Islander or Maori descent, any dialysis, any prior smoking,
vascular disease, diabetes, respiratory disease and greater than 18 hour ischaemia time were
linked to reduced patient survival than their counterparts (S2 Table). Asian descent, glomeru-
lonephritis, polycystic kidney disease and reflux nephropathy were linked to increased patient
survival. Blood group A, B and AB recipients had similar post-transplant survivals compared
to blood group O recipients (Fig 1B, S3 Table).
On competing risk analyses, blood group O was associated with 18% increased risk of can-
cer-related mortality (HR 1.18, 95% CI 1.01–1.37, Fig 2). However, this became statistically
insignificant on multivariate analyses (HR 1.14, 95% CI 0.97–1.34). ABO blood group were
not associated with differences in mortality from cardiovascular disease, infection nor with-
drawal from dialysis.
Recipient blood group AB associated with inferior death censored graft
survival
While there was no difference in death censored graft survival between blood group O and
non-O blood groups (HR 0.97, 95% CI 0.89–1.05, Fig 3A, S4 Table), blood group AB recipient
had inferior death censored graft survival compared to blood group O (HR 1.24, 95% CI 1.02–
1.50; S5 Table, Fig 3B). BMI�30, Aboriginal and Torres Strait Islander, Maori or Pacific
descent, dialysis greater than 2 years, current smoking, vascular disease, diabetes,�3 HLA
mismatches, increasing donor age>50 years old were linked to reduced graft survival (S5
Table). Later transplant vintage was associated with improved graft survival.
Discussion
On analysis of 15, 523 kidney transplant patients in Australia and New Zealand between 1995–
2016, recipient blood group O had similar patient survival post-transplant compared to non-O
blood groups. This is similar to findings in 854 lung transplant patients where recipient ABO
blood group was not an independent risk factor for one-year post-transplant survival [18].
These results suggest that ABO blood group antigen may not significantly affect post-trans-
plant survival. Conversely in 557 liver transplant patients, recipient blood group O was associ-
ated with reduced post-transplant survival compared to non-O blood groups (HR 1.75, 95%
CI 1.04–2.87, p = 0.035) [19]. However, patients with blood group O are known to have longer
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Table 1. Patient characteristics at transplant between ABO groups (n = 15,523).
Characteristics All; n (%) ABO group
O; n(%) A; n (%) B; n (%) AB; n(%)
N 15,523 6839 (44.1) 6,166 (39.7) 1769 (11.4) 639 (4.1)
Age at transplant, y, median (IQR) 48.0 (35.0–58.0) 48.0 (35.0–58.0) 48.0 (36.0–58.0) 48.0 (36.0–57.0) 49.0 (37.0–58.0)
Age group, y
<15 623 (4.0) 273 (4.0) 243 (3.9) 67 (3.8) 25 (3.9)
15–44 5,954 (38.4) 2686 (39.3) 2,356 (38.2) 652 (36.9) 220 (34.4)
45–54 3,818 (24.6) 1632 (23.9) 1,522 (24.7) 469 (26.5) 173 (27.1)
55–64 3,722 (24.0) 1649 (24.1) 1,471 (23.9) 414 (23.4) 160 (25.0)
65+ 1,406 (9.1) 599 (8.8) 574 (9.3) 167 (9.4) 61 (9.5)
Gender
Male 9,658 (62.2) 4281 (62.6) 3,808 (61.8) 1097 (62.0) 402 (62.9)
Female 5,865 (37.8) 2558 (37.4) 2,358 (38.2) 672 (38.0) 237 (37.1)
BMI, kg/m2
<18.5 492 (3.2) 218 (3.2) 170 (2.8) 78 (4.4) 22 (3.4)
18.5–24.9 6,085 (39.2) 2714 (39.7) 2,349 (38.1) 733 (41.4) 252 (39.4)
25–29.9 5,117 (33.0) 2259 (33.0) 2,062 (33.4) 554 (31.3) 214 (33.5)
> = 30 2,998 (19.3) 1265 (18.5) 1,276 (20.7) 319 (18.0) 124 (19.4)
Missing 831 (5.4%) 383 (5.6) 309 (5.0) 85 (4.8) 27 (4.2)
Ethnicity
White 12268 (79.0) 5545 (81.1) 5,014 (81.3) 1184 (66.9) 444 (69.5)
ATSI 488 (3.1) 230 (3.4) 223 (3.6) 23 (1.3) 11 (1.7)
Asian 1,520 (9.8) 579 (8.5) 389 (6.3) 426 (24.1) 121 (18.9)
Maori 404 (2.6) 153 (2.2) 216 (3.5) 18 (1.0) 15 (2.3)
Pacific 439 (2.8) 171 (2.5) 176 (2.9) 62 (3.5) 22 (3.4)
Other 287 (1.8) 118 (1.7) 104 (1.7) 44 (2.5) 21 (3.3)
Missing 117 (0.9) 43 (0.6) 44 (0.7) 12 (0.7) 5 (0.8)
Primary renal disease
Diabetic Nephropathy 2,157 (13.9) 928 (13.6) 869 (14.1) 242 (13.7) 107 (16.7)
Glomerulonephritis 6,624 (42.7) 2904 (42.5) 2,606 (42.3) 807 (45.6) 277 (43.3)
Hypertension 811 (5.2) 354 (5.2) 318 (5.2) 92 (5.2) 41 (6.4)
Polycystic Disease 2,128 (13.7) 975 (14.3) 840 (13.6) 215 (12.2) 78 (12.2)
Reflux Nephropathy 1,240 (8.0) 555 (8.1) 503 (8.2) 132 (7.5) 44 (6.9)
Other/Uncertain 2,489 (16.0) 1096 (16.0) 1,004 (16.3) 272 (15.4) 91 (14.2)
Missing 74 (0.5) 27 (0.4) 26 (0.4) 9 (0.5) 1 (0.2)
Dialysis duration, y, median (IQR) 1.9 (0.7–3.8) 2.3 (0.8–4.4) 1.6 (0.6–3.2) 2.1 (0.8–4.2) 1.2 (0.5–2.2)
Dialysis duration, y
Pre-emptive 1,877 (12.1) 778 (11.4) 803 (13.0) 179 (10.1) 77 (12.1)
�1 6,197 (39.9) 2,381 (34.8) 2,725 (44.2) 663 (37.5) 381 (59.6)
2–3 3,833 (24.7) 1,745 (25.5) 1,487 (24.1) 457 (25.8) 130 (20.3)
�4 3,616 (23.3) 1,935 (28.3) 1,151 (18.7) 470 (26.6) 51 (8.0)
Smoking status
Never 8,948 (57.6) 3942 (57.6) 3,541 (57.4) 1047 (59.2) 348 (54.5)
Former 4,833 (31.1) 2107 (30.8) 1,948 (31.6) 523 (29.6) 229 (35.8)
Current 1,590 (10.2) 715 (10.5) 629 (10.2) 181 (10.2) 58 (9.1)
Missing 152 (1.0) 75 (1.1) 48 (0.9) 18 (1.0) 4 (0.6)
Vascular disease 3,224 (20.8) 1406 (20.6) 1,290 (20.9) 374 (21.1) 144 (22.5)
Missing 64 (0.4) 27 (0.4) 22 (0.4) 8 (0.5) 3 (0.5)
(Continued)
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waitlist times for liver transplant compared to those with non-O blood groups—potentially
contributing to the observed reduced patient survival [20].
Competing risks analyses demonstrated that blood group O were at increased risk of can-
cer-related mortality compared to non-blood group O recipients on univariate analyses. This
Table 1. (Continued)
Characteristics All; n (%) ABO group
O; n(%) A; n (%) B; n (%) AB; n(%)
Diabetes 2,839 (18.3) 1227 (17.9) 1,125 (18.2) 337 (19.1) 136 (21.3)
Missing 63 (0.4) 25 (0.4) 22 (0.4) 8 (0.5) 3 (0.5)
Respiratory disease 974 (6.3) 438 (6.4) 370 (6.0) 121 (6.8) 40 (6.3)
Missing 64 (0.4) 28 (0.4) 21 (0.3) 8 (0.5) 3 (0.5)
Total ischemia time, h, Median (IQR) 9.0 (3.0–14.0) 9.0 (3.0–14.0) 9.0 (3.0–14.0) 9.0 (4.0–14.0) 11.0 (5.0–15.0)
Total ischemia time, h
<12h 9,249 (59.6) 4047 (59.2) 3,746 (60.8) 1055 (59.6) 319 (49.9)
12h-18h 4,511 (29.1) 1999 (29.2) 1,752 (28.4) 520 (29.4) 232 (36.3)
18h+ 1,309 (8.4) 605 (8.8) 498 (8.1) 137 (7.7) 68 (10.6)
Missing 454 (2.9) 188 (2.7) 170 (2.8) 57 (3.2) 20 (3.1)
HLA mismatches
0 970 (6.2) 428 (6.3) 360 (5.8) 82 (4.6) 23 (3.6)
1 1,291 (8.3) 662 (9.7) 484 (7.8) 114 (6.4) 31 (4.9)
2 3,163 (20.4) 1569 (22.9) 1,237 (20.1) 275 (15.5) 74 (11.6)
3 3,112 (20.0) 1432 (20.9) 1,239 (20.1) 330 (18.7) 100 (15.6)
4 2,526 (16.3) 1028 (15.0) 993 (16.1) 360 (20.4) 138 (21.6)
5 2,960 (19.1) 1098 (16.1) 1,246 (20.2) 424 (24.0) 187 (29.3)
6 1,501 (9.7) 622 (9.1) 607 (9.8) 184 (10.4) 86 (13.5)
Type of Donors
Live 5,591 (36.0) 2485 (36.3) 2,277 (36.9) 576 (32.6) 162 (25.4)
Deceased 9,932 (64.0) 4354 (63.7) 3,889 (63.1) 1193 (67.4) 477 (74.6)
Donor age, y, median (IQR) 46.0 (31.0–56.0) 46.0 (31.0–56.0) 46.0 (32.0–57.0) 45.0 (29.0–55.0) 44.0 (29.0–56.0)
Donor age group, y
<25 2,782 (17.9) 1264 (18.5) 1,063 (17.2) 317 (17.9) 131 (20.5)
25–34 1,711 (11.0) 718 (10.5) 687 (11.1) 220 (12.4) 76 (11.9)
35–44 2,710 (17.5) 1171 (17.1) 1,088 (17.6) 314 (17.8) 114 (17.8)
45–54 3,768 (24.3) 1669 (24.4) 1,501 (24.3) 434 (24.5) 132 (20.7)
55–64 3,133 (20.2) 1354 (19.8) 1,263 (20.5) 343 (19.4) 145 (22.7)
65+ 1,392 (9.0) 648 (9.5) 558 (9.0) 139 (7.9) 41 (6.4)
Missing 27 (0.2) 15 (0.2) 6 (0.1) 2 (0.1) -
Donor gender
Male 7,768 (50.0) 3409 (49.8) 3,027 (49.1) 940 (53.1) 348 (54.5)
Female 7,118 (45.9) 3145 (46.0) 2,880 (46.7) 759 (42.9) 273 (42.7)
Missing 637 (4.1) 285 (4.2) 259 (4.2) 70 (4.0) 18 (2.8)
Era
1995–1999 2,545 (16.4) 1109 (16.2) 1,014 (16.4) 312 (17.6) 109 (17.1)
2000–2004 3,042 (19.6) 1344 (19.7) 1,273 (20.6) 299 (16.9) 126 (19.7)
2005–2009 3,496 (22.5) 1588 (23.2) 1,355 (22.0) 412 (23.3) 140 (21.9)
2010–2016 6,440 (41.5) 2798 (40.9) 2,524 (40.9) 746 (42.2) 264 (41.3)
Data were presented as N (%) unless stated otherwise; IQR 75th– 25th percentile.
ATSI Aboriginal and Torres Strait Islanders.
https://doi.org/10.1371/journal.pone.0236396.t001
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may be associated with increased risks of skin cancer and non-hodgkin’s lymphoma in blood
group O patients [10–12]—both of which are linked to higher risks of cancer-related mortality
in Australian and New Zealand renal transplant patients between 1980 to 2014 [21]. Addition-
ally, blood group O recipients had the longest pre-transplant dialysis duration. Dialysis has
been associated with increased risks of oral, colorectal, liver, blood, breast, renal, upper urinary
tract, and bladder cancer in population cohort studies [22, 23]. This could be due to dialysis-
Fig 1. Kaplan Meier survival curve for cumulative patient survival post-transplant by recipient ABO blood group. (A) Recipient blood group O vs.
non-blood group O. (B) All recipient blood groups.
https://doi.org/10.1371/journal.pone.0236396.g001
Fig 2. Univariate and multivariate competing risk analysis of cause-specific patient mortality between O and non-
O ABO group. The estimates show the subdistribution hazards ratio for ABO O group where non-O ABO group is the
reference point.
https://doi.org/10.1371/journal.pone.0236396.g002
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related immune dysfunction however, no differences in infection related mortality were
observed. It is more likely that the combination of chronic infection, inflammation, immune
dysfunction, malnutrition, and shortage of DNA repair mechanisms associated with dialysis
promotes tumorigenesis [24, 25]. Unfortunately, data regarding the type of cancer was not
available and is a limitation of this study. Further studies are required to investigate the effect
of recipient ABO blood groups on the incidence of cancer subtypes post-transplant.
Recipient blood group AB was associated reduced death censored graft survival compared
to blood group O. Notably, recipients with AB blood group only comprised 4.11% (639/
15,523) of kidney transplants; and had different ethnicity distribution, pre-transplant dialysis
duration, prolonged total ischemia time, donor type, donor age and transplant era compared
to non-AB blood group recipients. Furthermore, it is a highly heterogenous population in
terms of duration of pre-transplant renal replacement therapy, recipient and donor factors
owing to the variable supply of donor AB blood group kidney grafts [26]. As a result, the infe-
rior death-censored graft survival observed in this study may not be generalized to all AB
blood groups recipients.
Moreover, recipient blood group may be a surrogate marker for established adverse out-
come factors. This is supported by differences in recipient BMI, ethnicity, pre-transplant renal
replacement therapy, total ischaemia time, HLA mismatch and donor type by recipient blood
group. For example, pre-transplant obesity is associated with increased mortality and death-
censored graft survival in a meta-analysis of 10 adult studies [27]. Aboriginal and Torres
Strait Islander recipients have prolonged wait times, increased number of HLA mismatches,
enhanced socioeconomic barriers to ongoing treatment and shortened recipient survival com-
pared to non-Aboriginal and Torres Strait Islander Australians [28]. However, differences in
survival in Aboriginal and Torres Strait Islander Australians have primarily been attributed to
infective causes which was not observed in this study [29]. Pre-emptive kidney transplants and
living donor grafts are associated with improved patient and graft survival [30].
Increasing recipient age, longer duration of pre-transplant renal replacement therapy, cur-
rent smoking status, vascular disease, diabetes mellitus, deceased donor and early era of trans-
plant are independent risk factors for adverse post-transplant patient outcomes per meta-
analyses [31] along with, database analyses of US [32–35], Australian, New Zealand [36], and
Dutch [30] recipients.
Fig 3. Kaplan Meier survival curve for death censored graft survival by recipient ABO blood group. (A) Recipient blood group O vs. non-blood
group O. (B) All recipient blood groups.
https://doi.org/10.1371/journal.pone.0236396.g003
PLOS ONE Blood group relationships to kidney transplant outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0236396 July 23, 2020 8 / 11
The major strength of this study is the use of a large registry with almost complete capture
from time of dialysis initiation to graft loss and/or mortality. However, the use of observational
data carries inherent risks related to confounding factors. Multivariate analyses can be used to
control for known confounders however, it cannot address unmeasured confounders such as
socioeconomic status, nutrition and environmental exposures. It follows that blood group A
may be a surrogate marker for an unmeasured factor such as geographic location, family his-
tory of heart disease or financial status.
Additionally, the findings of this study are primarily applicable to the Australian and New
Zealand population and health infrastructure. Further studies using other databases such as
United States Renal Data System and United Kingdom Renal Registry could be completed
to determine if the correlations observed in this study are translatable to other jurisdictions.
Lastly, this study did not investigate if there was a link between rates of acute or chronic rejec-
tion and recipient ABO blood group. The effect of recipient ABO blood group on causes of
death-censored graft failure were not investigated.
Conclusions
Recipient blood group O was not associated with differences in all-cause mortality. There may
be ABO blood group effects on cause-specific (e.g. cancer-related) mortality. Recipient blood
group AB was associated with reduced death censored graft survival however, this is difficult
to interpret in the context of the small highly heterogenous patient population included in this
study. Further investigations in larger populations are required to clarify the effects of specific
ABO blood groups on all-cause mortality and cause-specific mortality.
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